TAE226 (NVP-TAE226) 化学構造
分子量: 468.94

品質と確認

カスタマーレビュー(1)

Quality Control & MSDS

製品情報

  • Compare FAK Inhibitors
    FAK阻害剤を比較
  • 研究分野

製品の説明

生物活性

情報 TAE226 (NVP-TAE226)、強力な二重FAK/IGF-IR、 FAK とIGF-IRを妨げて、IC50 がそれぞれ 5.5 nM と 0.14 μMです。
目標 FAK IGF-1R Pyk2
IC50 5.5 nM 0.14 μM 3.5 nM [1]
In vitro試験 NVP-TAE226 (< 1 μM) inhibits extracellular matrix-induced autophosphorylation of FAK (Tyr397) in serum-starved U87 cells. NVP-TAE226 (< 1 μM) also inhibits IGF-I-induced phosphorylation of IGF-1R and activity of its downstream target genes such as MAPK and Akt in both U87 and U251 cells. NVP-TAE226 (<10 μM) retards tumor cell growth and attenuats G(2)-M cell cycle progression associated with a decrease in cyclin B1 and phosphorylated cdc2 (Tyr15) protein expression in both U87 and U251 cells. NVP-TAE226 (1 μM) inhibits tumor cell invasion by at least 50% compared with the control in an in vitro Matrigel invasion assay in glioma cell lines. NVP-TAE226 (1 μM) treatment of glioma cell lines containing wild-type p53 mainly exhibits G(2)-M arrest, whereas glioma cell lines bearing mutant p53 undergoes apoptosis, as evidence by detection of caspase-3/7 activation and poly(ADP-ribose) polymerase cleavage and by an Annexin V apoptosis assay. [1] NVP-TAE226 (5 μM) inhibits phosphorylation of FAK in the human neuroblastoma cell line SK-N-AS. NVP-TAE226 (<10 μM) treatment of the human neuroblastoma cell line SK-N-AS leads to decrease in cellular viability, cell cycle arrest, and an increase in apoptosis. [2] NVP-TAE226 (0.1 μM-10 μM) inhibits tube formation of HMEC1 cells. [3]
In vivo試験 NVP-TAE226 (75 mg/kg) significantly increases the survival rate of mice bearing intracranial glioma xenografts. [1] NVP-TAE226 (100 mg/kg, oral) exerts significant decrease in microvessel density in a human colon cancer model in SCID mice. [3] NVP-TAE226 (100 mg/kg, oral) efficiently inhibits MIA PaCa-2 human pancreatic tumor growth without body weight loss in vivo model. [4] NVP-TAE226 inhibits 4T1 murine breast tumor growth and metastasis to the lung in a dose-dependent manner in vivo model, associated with inhibition of FAK autophosphorylation at Y397 and Akt phosphorylation at Serine473. [5]
臨床試験
特集

推薦された実験操作 (公開の文献だけ)

細胞アッセイ: [1]

細胞系 U87 and U251 cell lines
濃度 10 μM
処理時間 5 days
方法 Cell cultures are harvested with 0.05% trypsin and seeded in triplicate at 2 × 104 in 24-well culture plates for 24 h before drug treatment. Culture medium is used for mock treatment. Cells are harvested at the indicated day after treatment, and viable cells are counted using the Vi-cell viability analyze

動物実験: [1]

動物モデル Male nude mice bearing intracranial glioma xenografts
製剤 0.5% methylcellulose
投薬量 75 mg/kg
管理 Administered via oral gavage
Solubility 0.5% methylcellulose, 30 mg/mL
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesBaboonDogMonkeyRabbitGuinea pigRatHamsterMouse
Weight (kg)121031.80.40.150.080.02
Body Surface Area (m2)0.60.50.240.150.050.0250.020.007
Km factor202012128653
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download TAE226 (NVP-TAE226) SDF
分子量 468.94
化学式

C23H25ClN6O3

CAS No. 761437-28-9
保管 2年-20℃
6月-80℃in DMSO
別名
溶解度 (25°C) * In vitro DMSO 94 mg/mL (200 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 0.5% methylcellulose, 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-

研究分野

カスタマーレビュー (1)


Click to enlarge
Rating
Source Cell Death Dis, 2014, 20, 5:e1134. TAE226 (NVP-TAE226) purchased from Selleck
Method Hemocytometer
Cell Lines Red blood cells
Concentrations 0.5 uM
Incubation Time 72 h
Results TAE226, GSK1120212 and BKM120 were able to induce synergistic cell death in combination with LBH589 validating that resistance to HDACi can be overcome by targeting actin cytoskeleton related signaling cascades. In all assays, the proportion of death induced in non-MM compartment was also assessed and ranged between 4 and 25% confirming the existence of a potential therapeutic window for the combinations evaluated.

製品表彰状 (1)

技術サポート&よくある質問(FAQ)

顧客がするかもしれない質問に対する答えは、指示を取り扱っている阻害剤で見つかります。話題は、貯蔵液(阻害剤と特別な注意を細胞ベースの分析法と動物のために必要とする問題を保存することは実験します)を準備する方法を含みます。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の問い合わせをするならば、メッセージを残してください。

* 必須

Related FAK 阻害剤

  • PF-562271 HCl

    PF-562271 HCl is the hydrochloride salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.

  • GS-9973

    GS-9973 is an orally bioavailable, selective Syk inhibitor with IC50 of 7.7 nM.

  • AVL-292

    AVL-292 is a covalent, orally active, and highly selective BTK inhibitor with IC50 of <0.5 nM, displaying at least 1400-fold selectivity over the other kinases assayed. Phase 1.

  • SSR128129E

    SSR128129E is an orally-active and allosteric FGFR inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs.

  • PF-00562271

    PF-00562271は、焦点粘着力キナーゼ(FAK)とPyk2触媒活性の強力な、ATP競争的、可逆的な阻害剤で、IC50 がそれぞれ 1.5 nM と 14 nMです。

  • PF-562271

    PF-562271 is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs.

  • PF-573228

    PF-573228 は FAKの阻害剤で、IC50 が 4 nMです。

  • Ibrutinib (PCI-32765)

    Ibrutinib (PCI-32765)は、0.5nMのIC50による有力で非常に選択的なブラットンのチロシン・キナーゼ(Btk)阻害剤です。

  • Dasatinib

    Dasatinib は、野生型ablとSrcのためのSrc/abl阻害剤で、IC50 がそれぞれ 0.6 nM と 0.8 nMです。

最近見られたアイテム

Tags: TAE226 (NVP-TAE226)を買う | TAE226 (NVP-TAE226)供給者 | TAE226 (NVP-TAE226)を購入する | TAE226 (NVP-TAE226)費用 | TAE226 (NVP-TAE226)生産者 | オーダーTAE226 (NVP-TAE226) | TAE226 (NVP-TAE226)代理店
お問い合わせ